Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBloomsbury Regulatory News (BMY)

Share Price Information for Bloomsbury (BMY)

Share Price is delayed by 15 minutes
Get Live Data
656.00    2.00 (0.31%)
Bid:
658.00
Ask:
660.00
Spread: 2.00 (0.304%)
Market Cap: £533.96m
BMY Live PriceLast checked at - London Stock Exchange

Intraday Bloomsbury Share Chart

Acquisition

6 Jan 2009 08:41

RNS Number : 1619L
Bloomsbury Publishing PLC
06 January 2009
 



 

Bloomsbury Publishing Plc

("Bloomsbury")

Bloomsbury acquires Arden Shakespeare

Bloomsbury Publishing Plc is pleased to announce the acquisition of Arden Shakespeare from Cengage Learning. This transaction is not material to Bloomsbury.

  Arden Shakespeare is the most academically rigorous Shakespeare series in print, and the best-known English literature brand worldwide. Originally created by the British publishing firm of Methuen in the late nineteenth century, and edited by a distinguished collection of scholars, the series took 25 years to complete from the launch of the first title, Edward Dowden's Hamlet, in 1899. In 1995 the Third Series of The Arden Shakespeare was launched. Now published under the imprint Arden Shakespeare, under the General Editorship of Richard Proudfoot, Ann Thompson, David Scott Kastan and Henry Woudhuysen, the Arden Shakespeare Third Series is nearing completion. Each new volume supersedes the corresponding Second Series text, being meticulously edited from the original sources by a contemporary scholar.

Arden Shakespeare will retain its internationally recognised name and become part of the Methuen Drama imprint (acquired in 2006 by A&C Black which is a wholly owned subsidiary of Bloomsbury). The acquisition will make Methuen Drama Europe's largest performing arts list, which includes work by Bertolt Brecht, Oscar Wilde, Bernard Shaw and Arthur Miller as well as contemporary playwrights such as Michael Frayn and Willy Russell, Methuen Student editions and the New Mermaids critical editions.

'I am delighted that the Arden Shakespeare series is returning to MethuenArden is a highly prestigious addition to our performing arts publishing and fits perfectly with our strategy of acquiring high quality perennial publishing lists which have significant potential for digital exploitation. We look forward to working with the Arden General Editors Richard Proudfoot, Ann Thompson, David Scott Kastan and Henry Woudhuysen to grow and strengthen this important list' says A&C Black Managing Director, Jill Coleman.

Jill Jones, CEO Cengage Learning EMEA said, 'The Arden Shakespeare is an excellent fit for Bloomsbury: we wish A&C Black, all volume editors, authors and General Editors from the Arden Shakespeare success for the future'.

www.methuendrama.com

-ends-

For further enquiries:

Bloomsbury Publishing PLC

Jill Coleman, Bloomsbury Publishing Plc care of Bell Pottinger

Bell Pottinger Corporate & Financial

Ben Woodford / Rosanne Perry +44 (0)20 7861 3232

Notes to Editors

About Bloomsbury Publishing Plc 

(www.bloomsbury.com and www.bloomsbury-ir.co.uk)

Bloomsbury Publishing is one of the world's leading independentpublicly quoted publishing houses with a reputation for a high quality management team and a highly valuable portfolio of intellectual properties including the Encarta World English Dictionary, JK Rowling's Harry Potter, Margaret Atwood, John Irving, David Guterson and Ben Schott. Other databases include Who's Who, Whitaker's AlmanackReed's Nautical Almanac, Black's Medical Dictionary, the Macmillan English Dictionary for Advanced Learners of EnglishBusiness: The Ultimate Resource and RSPB Handbook of British Birds. 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
ACQUNOWRKKRARRR
Date   Source Headline
9th Jul 20096:18 pmRNSHolding(s) in Company
1st Jul 20097:00 amRNSAcquisition
18th Jun 200912:03 pmRNSHolding(s) in Company
8th Jun 200911:58 amRNSHolding(s) in Company
29th May 20094:36 pmRNSResult of AGM
15th May 20097:00 amRNSInterim Management Statement
14th May 20096:06 pmRNSHolding(s) in Company
13th May 20094:35 pmRNSPrice Monitoring Extension
8th May 20092:49 pmRNSHolding(s) in Company
6th May 20094:40 pmRNSSecond Price Monitoring Extn
6th May 20094:35 pmRNSPrice Monitoring Extension
5th May 20094:12 pmRNSHolding(s) in Company
28th Apr 20096:21 pmRNSHolding(s) in Company
24th Apr 20093:42 pmRNSHolding(s) in Company
24th Apr 20093:40 pmRNSHolding(s) in Company
20th Apr 20093:34 pmRNSHolding(s) in Company
9th Apr 200911:27 amRNSHolding(s) in Company
3rd Apr 20094:17 pmRNSHolding(s) in Company
1st Apr 200910:43 amRNSDividend Record Date
31st Mar 20097:00 amRNSFinal Results
13th Mar 20094:40 pmRNSSecond Price Monitoring Extn
13th Mar 20094:35 pmRNSPrice Monitoring Extension
4th Mar 20098:54 amRNSHolding(s) in Company
17th Feb 200912:29 pmRNSHolding(s) in Company
5th Feb 20093:59 pmRNSHolding(s) in Company
4th Feb 200912:27 pmRNSHolding(s) in Company
3rd Feb 20095:01 pmRNSHolding(s) in Company
15th Jan 20097:00 amRNSTrading Statement
6th Jan 20098:41 amRNSAcquisition
16th Dec 20084:40 pmRNSHolding(s) in Company
5th Dec 20087:00 amRNSAcquisition
17th Nov 20084:00 pmRNSHolding(s) in Company
4th Nov 20085:40 pmRNSHolding(s) in Company
17th Oct 20085:40 pmRNSDirector/PDMR Shareholding
16th Oct 20085:27 pmRNSHolding(s) in Company
15th Oct 20087:00 amRNSInterim Management Statement
14th Oct 20085:41 pmRNSHolding(s) in Company
13th Oct 200812:28 pmRNSHolding(s) in Company
9th Oct 20083:42 pmRNSHolding(s) in Company
30th Sep 20084:27 pmRNSAllotment of shares
25th Sep 20087:00 amRNSAcquisition
29th Aug 20087:00 amRNSInterim Results
21st Aug 200811:50 amRNSHolding(s) in Company
24th Jul 200811:55 amRNSNotice of Results
23rd Jul 200811:53 amRNSHolding(s) in Company
2nd Jul 20086:26 pmRNSResult of AGM - Replacement
30th Jun 200810:31 amRNSResult of AGM
27th Jun 20087:21 amRNSAGM Statement
12th Jun 20083:51 pmRNSHolding(s) in Company
11th Jun 200811:01 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.